Effective methods of serial epithelial sampling to measure breast-specific biomarkers will aid the rapid evaluation of new preventive interventions. We report here a proofof-principle phase 2 study to assess the utility of ductal lavage (DL) to measure biomarkers of tamoxifen action. We enrolled women with a 5-year breast cancer risk estimate >1.6% or the unaffected breast of women with T 1a or T 1b breast cancer. After entry DL, participants chose tamoxifen or observation and underwent repeat DL 6 months later. Samples were processed for cytology and immunohistochemistry for estrogen receptor α, Ki-67, and cyclooxygenase-2. Of 182 women recruited, 115 (63%) underwent entry and repeat DL; 85 (47%) had sufficient cells for analysis from ≥1 duct at both time points; in 78 (43%), cells were sufficient from ≥1 matched ducts. Forty-six women chose observation and 39 chose tamoxifen. We observed greater reductions in the tamoxifen group than in the observation group for Ki-67 (adjusted P = 0.03) and estrogen receptor α (adjusted P = 0.07), but not in cyclooxygenase-2 (adjusted P = 0.4) labeling. Cytologic findings showed a trend toward improvement in the tamoxifen group compared with the observation group. Interobserver variability for cytologic diagnosis between two observers showed good agreement (κ = 0.44). Using DL, we observed the expected changes in tamoxifen-related biomarkers; however, poor reproducibility of biomarkers in the observation group, the 53% attrition rate of subjects from recruitment to biomarker analyses, and the expense of DL are significant barriers to the use of this procedure for biomarker assessment over time.Ductal lavage (DL) is a minimally invasive technique that allows sampling of breast ductal epithelium in healthy high-risk women with a significantly better cell yield compared with nipple aspirate fluid (1-3). This allows the possibility of monitoring response to prevention agents by serial sampling of epithelial cells, using biomarkers relevant to the agent being tested. Thus, DL is a potentially attractive tool for assessing the effects of chemoprevention agents (1).To establish the principle that biomarkers of chemoprevention agents can be monitored using DL, we initiated a phase 2, nonrandomized trial using tamoxifen, the gold-standard breast cancer chemoprevention agent (4). We reasoned that the efficacy of tamoxifen in the prevention of estrogen receptor (ER)-positive breast cancer has been clearly shown and a study using tamoxifen as the preventive intervention should enable the efficient evaluation of DL as a tool for repeat epithelial sampling in phase 2 prevention studies. Furthermore, because tamoxifen does not prevent all breast cancer cases, if markers of tamoxifen efficacy could be identified it may be possible to target therapy to those most likely to benefit from it.We now report the final results of this trial, having recruited 182 women, of whom 85 were evaluated for biomarker results at two time points. We present a comparative analysis of women who accepted ...